Skip to main content

Dubow Adam's Form 4 filing

Day One Biopharmaceuticals, Inc. (DAWN) · filed Feb 20, 2024

Accession no.
0001415889-24-004473
Filed
Feb 20, 2024
Trade date
Feb 15-16, 2024
Filing delay
5 days
Rule 10b5-1 plan
Not checked

This filing lists 4 non-derivative transactions and 3 derivative transactions. Open-market sales total $49.4K. It was filed 5 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Dubow AdamCIK 0001744507Officer (GENERAL COUNSEL)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Feb 15, 2024Common StockMOption exerciseAcquired+2,962––14,390Direct
Feb 15, 2024Common StockMOption exerciseAcquired+1,750––16,140Direct
Feb 15, 2024Common StockMOption exerciseAcquired+3,687––19,827Direct
Feb 16, 2024Common StockSSaleDisposed−3,242$15.25−$49,440.516,585Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Feb 15, 2024Common StockMOption exerciseDisposed−2,962$0.00$032,588Direct
Feb 15, 2024Common StockMOption exerciseDisposed−1,750$0.00$019,250Direct
Feb 15, 2024Common StockMOption exerciseDisposed−3,687$0.00$055,313Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)